Background. Detection rates of depression in primary care are <50%. Studies showed similar outcome after 12 months for recognized and unrecognized depression. Outcome beyond 12 months is less well studied.
Introduction
Unipolar major depressive disorder (MDD) is predicted to be the second cause of disability worldwide in 2030. This is due to the high prevalence of depression, ranging from 10% to 25% in women and 5% to 12% in men, and its impact on daily functioning and mortality. 1 Most patients suffering from depression are treated by their primary care physician, 2 although the effect of treatment is the strongest in the patients with severe depressive symptoms. 3 Studies have shown that a shorter interval between onset of depression and start of treatment is associated with a better prognosis, thus early recognition in these patients is warranted. 4 A recent meta-analysis revealed that GPs identified depression in 47% of the cases of which 34% was recorded in their notes. 5 Diagnostic sensitivity was larger in studies that used a longer time interval (53%) compared to cross-sectional data (34%). 5, 6 Depressed patients who are not recognized in primary care may not receive the medical attention or treatment they need, which might worsen their prognosis. So far, few studies investigated the effect of recognition of depression in primary care in relation to outcome, and only one had a follow-up beyond 12 months. Patients recognized by their GP had more depressive symptoms at baseline than patients not recognized, while after 12 months, both groups had the same outcome. [7] [8] [9] [10] One study showed an increased risk of depression persistence after 5 years for depressed patients who were recognized compared to non-depressed patients, though the authors did not compare the outcome with unrecognized depressed patients. 11 None of these studies took baseline severity and a history of depressive symptoms into account, while these are strong predictors of both recognition and a poor outcome.
We aimed to determine the proportion of patients with MDD in primary care that was recorded and/or treated by GPs. Secondly, we investigated to what extent recognition affected the outcome of MDD.
Methods

Study setting and design
We used data from the PREDICT-NL study, which is the Dutch part of the predictD study. [12] [13] [14] [15] [16] [17] PredictD is a multicenter prospective cohort study from which a multifactor risk algorithm was developed to predict risk of onset of MDD in primary care patients in six European countries and Chile. PREDICT-NL is described in greater detail elsewhere.
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The PREDICT-NL study was approved by the Medical Ethics Committee of the University Medical Center Utrecht and all participants gave written informed consent.
Study participants
Consecutive patients aged >18 years were recruited in the waiting room of six primary care practices in Utrecht and surroundings between April 2003 and September 2004. Patients willing to participate were asked to fill in risk factor questionnaires and sign informed consent within 2 weeks. In total, 3089 consecutive patients were asked to take part, of whom 83 did not meet inclusion criteria. Exclusion criteria were an inability to understand one of the main languages involved, psychosis, dementia and incapacitating physical illness. Of the remaining 3006 participants, 1338 (45%) consented and took part in the study. Reasons for not participating were mostly lack of time (21%) and no interest (24%). Of the 1164 refusals on which we had demographic information (70%), we found no significant difference in age (mean 51 years with SD 19) and sex (62% female) distribution compared to our participants. Of the 1338 participants, 45 were excluded because no Composite International Diagnostic Interview (CIDI) was taken (n = 20) or no data from GPs was available (n = 25). Of the remaining 1293 participants, 1236 (96%) participated at the 6 months, 1179 (95% of 1236) at 12 months and 752 (69% of 1106 invited) at 39 months. Mean follow-up durations were 5.7 (SD 0.6), 12.0 (SD 0.6) and 39.2 months (SD 2.3).
Diagnosis of MDD
The diagnosis of MDD was assessed in all participants according to DSM-IV criteria using the depression section of the CIDI. 19, 20 MDD is characterized by one or more major depressive episodes (MDE) without a history of manic, mixed or hypomanic episodes. The essential feature of an MDE is presence of at least one of the two core symptoms (depressed mood and loss of interest or pleasure), which have to be present most of the day for a period of at least 2 weeks. In addition, four or more of the following symptoms have to be present for most of the time during the same period of at least 2 weeks in order to meet criteria for an MDE according to diagnostic criteria formalized in the DSM: fatigue or loss of energy, significant weight loss or gain, insomnia or hypersomnia, psychomotor agitation or retardation, concentration problems, feelings of worthlessness or guilt or recurrent suicidal ideation or thoughts of death. The researchers contacted the participant by telephone and asked the two core questions of the depression section of the CIDI interview (depressed mood or a loss of interest). 20 MDD was ruled out if the participant responded negatively to both questions. If the participant responded in the affirmative to one or both questions, an appointment was made in the general practice to conduct the entire CIDI depression interview. At baseline, the 6-and 12-month follow-up, diagnosis of MDD was assessed covering the preceding 6 months. At the 39-month follow-up, diagnosis of MDD was assessed covering the period between the 12-month and 39-month follow-up. If the participant was unable to schedule the interview at the general practice, the interview was done by telephone (23% of interviews at baseline, 17% at the 6-month follow-up and 19% at the 12-month follow-up). At the 39-month follow-up, all interviews were done by telephone. Studies have shown that both methods are comparable with respect to reliability and validity. 21, 22 Diagnosis and treatment of depression in primary care Depression recording and treatment by the GP were retrieved from their electronic patient records. The GPs were trained to diagnose according to the international classification of primary care (ICPC). 23 They were blinded to the CIDI diagnosis. ICPC codes from the electronic patient records were retrieved in the period 6 months before and 6 months after CIDI assessment. The total number of GP consultations during this year was calculated for each participant. In addition, a medical researcher manually searched the electronic patient records of participants diagnosed with MDD according to the CIDI at baseline. A positive diagnosis of depression was defined as either an ICPC code of P03 (feeling depressed) and P76 (depressive disorder) or a depression diagnosis retrieved by manual search. Treatment was defined as the prescription of anti-depressants (N06A) classified according to the Anatomical Therapeutic Chemical (ATC) classification system. In addition, ICPC codes of stress symptoms (P01, P02, P04, P05 and P06), neuraesthenia/surmenage (P78), anxiety disorder (P74), other psychiatric disorders and prescription of sedatives (N05BA, N05CD and N05CF) were retrieved for baseline analyses.
Severity of depressive symptoms (baseline depression severity score) The Patient Health Questionnaire 9 (PHQ-9) was included with the risk factor questionnaires. 24 It determines the presence of the nine DSM-IV criteria for MDD in the past 2 weeks on a four-point rating scale, ranging from 0 (not at all) to 3 ('nearly every day'). The scores on this questionnaire range from 0 to 27.
Mental function
Mental function was assessed by the Short Form 12 (SF-12), which yields a mental component summary (MCS) scale. 25, 26 The SF-12 yields a scale from 0 to 100, in which lower scores indicate greater dysfunction.
Covariates Patient characteristics at baseline included age, sex, marital status, presence of life events, level of education (11-point ordinal scale ranging from 'no education completed' to 'PhD level'), presence of one or more chronic diseases diagnosed by a physician and number of complaints presented to the GP. 24 A lifetime history of depressive symptoms was ruled out if the screen for two core symptoms of the lifetime CIDI depression section were absent. If one or two of the core symptoms were present, participants were considered to have a lifetime history of depressive symptoms. 27, 28 Data analysis Missing data rarely occur completely at random and a complete case analysis may lead to loss of statistical power and biased results. 29 We used multiple imputation (10 datasets) to address missing values using the statistical programme R (version 2.8.1). Data were analysed using PASW version 17.0 (IBM SPSS Statistics) by pooling the 10 imputed datasets.
Firstly, we computed the frequency of MDD at baseline and the proportion recognized by their GP and/or receiving anti-depressants. We divided the participants into three groups using the CIDI diagnosis as golden standard: (i) MDD according to the CIDI and depression recorded and/or treated by the GP (referred to as recognized depression), (ii) MDD according to the CIDI but depression not recorded and not treated by the GP (unrecognized depression) and (iii) no MDD according to the CIDI (no depression) regardless of whether depression was recorded by the GP (this occurred in 1% of the cases). We compared the following diagnostic groups: (i) participants with recognized depression to unrecognized depression and (ii) participants with unrecognized depression to no depression. Differences between the groups were tested with F-tests (analysis of variance) for continuous and with the chi-square tests for categorical variables.
Secondly, relative risks (RRs) were estimated with Poisson regression analyses with MDD according to a CIDI diagnosis after 39 months as the dependent variable. 30, 31 In the first model, we adjusted for age (continuous), female gender (yes versus no), lower education (yes versus no), living together (yes versus no) and one or more life events in the 6 months prior to baseline (yes versus no) as a priori confounders. In the second model, a history of depressive symptoms (yes versus no) and baseline depression severity score measured by the PHQ-9 (continuous) were added to the models.
Thirdly, random coefficient analyses with robust standard errors were performed to estimate marginal means for PHQ-9 and MCS at each assessment with the diagnostic group variable as independent variable. We used random intercept for best model fit. Diagnostic group, time and the interaction between diagnostic group and time were entered as independent variables. Analyses were adjusted for a priori confounders as mentioned above. Also, change in PHQ-9 and MCS over time, represented by the coefficients of interaction between the diagnostic group and time, was compared between recognized and unrecognized participants. We repeated the analyses in participants with no history of depressive symptoms and who were thus likely to have their first episode of depression.
Results
At baseline, 170 of 1293 patients had MDD in the 6 months prior to baseline (13.0%), of which 25% (n = 42) were recorded by the GP and 27% (n = 46) received anti-depressant medication in the period of 6 months before or after the CIDI interview was taken. Taking overlap into account, this resulted in 61 (36%) depressed participants who were recognized, 109 who were unrecognized and 1123 participants with no depression.
The mean age of the participants was 51 years and 63% were female (Table 1) . Participants with recognized depression were more often male and more often had a history of depressive symptoms than unrecognized participants. In addition, they had 36%) . Compared to non-depressed participants, unrecognized participants were younger and more often reported life events or had a history of depressive symptoms. Also, they received sedative drugs more often (35% versus 17%) and presented more often with complaints (30% versus 19%).
After 39 months, participants with recognized depression had an increased risk of being depressed [RR 1.51, 95% confidence interval (CI) 1.08-2.10]. This risk diminished and became non-significant after additional adjustment for history of depressive symptoms and baseline severity score (RR 1.35, 95% CI 0.68-2.68). Unrecognized participants had an increased risk of being depressed after 39 months compared to non-depressed participants (RR 2.68, 95% CI 1.54-4.66), which was mostly explained by a history of depressive symptoms and baseline severity (RR 1.31, 95% CI 0.69-2.49) ( Table 2) .
At baseline, participants with recognized depression had more depressive symptoms (mean difference PHQ-9 2.7, 95% CI 1.6-3.9) and worse mental function than unrecognized participants (mean difference MCS -3.8, 95% CI -7.8 to 0.2) (Fig. 1A and B) . At 12 and 39 months, the mean scores did not differ between these groups. Nevertheless, at 39 months, unrecognized participants had more depressive symptoms (mean difference PHQ-9 1.6, 95% CI 0.7-2.4) and worse mental function (mean difference MCS -5.2, 95% CI -7.6 to -2.8) than non-depressed participants. Participants with recognized depression had a greater, though non-significant, decline in severity of depressive symptoms over time and increase in mental function compared to unrecognized depression ( Table 3 ). These estimates did not change when a history of depressive symptoms was added to the models (Model 2). In participants with no history of depressive symptoms, there was a significant decline in depressive symptoms and significant increase in mental functioning over time for participants with recognized compared to unrecognized depression. At 39 months, recognized participants had a slightly, but not statistically significant, better outcome than unrecognized participants (mean difference PHQ-9 -1.1, 95% CI -3.5 to 1.3 and mean difference MCS 6.1, 95% CI -3.6 to 15.8) ( Fig. 2A and B) .
Discussion
We studied recognition of MDD and its relation to outcome after 6, 12 and 39 months in primary care. We observed that the GP recorded a depression diagnosis or depressive complaints or prescribed antidepressants in 36% of the depressed participants.
After 12 and 39 months, depression severity and mental functioning were similar between recognized and unrecognized patients, which were worse than non-depressed participants. To our knowledge, this is the first study with a relatively long follow-up period with several assessments. Previous studies either had a follow-up of 12 months with several assessments [7] [8] [9] [10] or a follow-up of 5 years but no assessments in between. 11 Another strength is that we were able to examine the natural course of recognition of depression because GPs were blinded to the CIDI diagnosis. Thirdly, we retrieved data on recognition and treatment of depression from the electronic patient records with use of ICPC and ATC codes as well as with manual search, which will have yielded more valid results than self-report. 11 Fourthly, MDD was diagnosed in an interview using DSM-IV criteria rather than relying on self-report symptom questionnaires.
A limitation of our study is that we had a low response rate at baseline, although similar participation rates have been found in other observational studies in primary care. 32 Patients with depression may be more reluctant to participate in a study due to loss of interest or apathy. On the other hand, they may have been more likely to participate in PREDICT-NL because the prognosis of depression is studied. The prevalence of 13% found in our study is higher than the 1-year prevalence of depression in the general population. 33 However, the prevalence of depression in primary care based on DSM-IV diagnosis is not known. Nevertheless, loss to follow-up was extremely low during the first 12 months of follow-up and after 39 months, loss to follow up was comparable for participants with unrecognized depression (42%) and no depression (42%) but somewhat lower for recognized depression (37%). Another limitation is that we had no data on the dose of anti-depressants prescription. In some cases, tricyclic anti-depressants (TCAs) are described in low dose for pain management, which we could not distinguish from the high-dose TCAs prescribed for depression. Thirdly, we had no data on treatment in second line nor were there data available on treatments such as psychotherapy, which may underestimate the part of recognized depression.
We found that only 25% of the depressed patients were recorded by the GP in the 6 months before or after they were diagnosed with MDD according to the CIDI. When we also included patients who were treated with anti-depressants recognition was still low (36%). Although the recorded proportion of 25% is slightly lower compared to a pooled sensitivity of 37% found in studies that used case notes of primary care with a follow-up from 3 to 12 months, 5 these results are in accordance with recognition rates of two other Dutch studies (21% and 29%). We observed that the risk of MDD after 39 months was higher for participants with recognized depression compared to unrecognized depression, which was mostly explained by presence of a history of depressive symptoms and a greater baseline severity score. This may resemble patients with severe therapy resistant depression.
Another study showed that patients with recognized depression also had a greater risk of being depressed after 5 years, but this was compared to patients with no depression and they did not account for baseline severity score. 11 In our study, participants with recognized depression had more depressive symptoms and worse mental function at baseline than those who were unrecognized, while after 12 months and 39 months, outcomes did not differ anymore. This is in agreement with results from previous studies with 12 months of follow-up. Moreover, those who were not recognized had a higher level of symptoms and greater dysfunction over time than those with no depression, although not significant.
Results of exploratory analyses in participants without a history of depressive symptoms suggest that participants with recognized depression had a significantly larger decrease in depressive symptoms and increase in mental function over time compared to unrecognized participants, suggesting that recognition or treatment of first episode MDD may lead to a more favourable course. However, the numbers of participants in our subgroups were very low and we could not calculate the risk of recurrence.
MDD accounts for a considerable part of the burden of disease. This is due to increasing incidence, its chronic nature and disability that causes absence from work and high health care costs. 1 Our results illustrate the chronic course of depression since both recognized and unrecognized depressed patients still had symptom levels above the threshold for mild depression and an increased risk of being depressed after 39 months compared to participants without depression at baseline. This course is not influenced by recognition or treatment by the GP since the outcome between both groups did not differ. This does not necessarily implicate that there is no need for the GPs to detect or treat depression. For example, the frequency of visits may indicate whether or not patients receive adequate social support from family and friends for their depressive complaints. Although persons with unrecognized depression visit their GP less often than those with recognized depression (36% versus 52%), and thus are less likely to be detected by the GP, our results suggest that those with unrecognized depression have a similar poor outcome as those with recognized depression. Despite that the level of social support may play a role in the perception of depressive symptoms and attitude towards health care, the level of social support did not prevent persons with unrecognized depression from having a poor course over time. While the outcome for both groups was comparable, the recognized patients had more symptoms at the outset of the research. A recent meta-analysis showed that treatment effect was only substantial in patients with severe depressive symptoms compared to patients with mild or moderate symptoms. 3 Apparently, GPs already detect the more severe cases of depression, who may benefit most from anti-depressant treatment. Moreover, in patients with a first episode of depression, recognition may improve outcome. Because a shorter interval between onset of depression and start of treatment is associated with a better prognosis, early recognition in these patients is warranted. 4 Clinical 
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FIGURE 2 Mean PHQ-9 (A) and MCS scores (B) for three diagnostic groups (with number of participants at baseline, 6, 12 and 39 months), adjusted for age (continuous), female gender (yes versus no), low education (yes versus no), living together (yes versus no), presence of life events (yes versus no) and history of depressive symptoms (yes versus no) in participants with no history of depressive symptoms
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